Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1815-1818

  Mueller, Brigitta U ^a,c   Anderson, Barry D ^a   Farley, Maureen Q ^a   Murphy, Robert ^a   Zuckerman, Judy ^a   Jarosinski, Paul ^b   Godwin, Karen ^a   McCully, Cindy L ^a   Mitsuya, Hiroaki ^a   Pizzo, Philip A ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KYNOSTATIN 272;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MACACA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031807756     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1815     Document Type: Article

References (25)

1. Balis, F. M., P. A. Pizzo, K. M. Butler, M. E. Hawkins, P. Brouwers, R. N. Husson, F. Jacobsen, S. M. Blaney, J. Gress, P. Jarosinski, and D. G. Poplack. 1992. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J. Infect. Dis. 165:99-104.
2. Balis, F. M., P. A. Pizzo, R. F. Murphy, J. Eddy, P. F. Jarosinski, J. Falloon, S. Broder, and D. G. Poplack. 1989. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann. Intern. Med. 110:279-285.
3. Blaney, S. M., M. J. Daniel, A. J. Harker, K. Godwin, and F. M. Balis. 1995. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob. Agents Chemother. 39:2779-2782.
4. Brouwers, P., A. Belman, and L. Epstein. 1994. Central nervous system involvement: Manifestations, evaluation, and pathogenesis, p. 318-335. In P. A. Pizzo and C. A. Wilfert (ed.). Pediatric AIDS. The challenge of HIV infection in infants, children, and adolescents. The Williams & Wilkins Co., Baltimore, Md.
5. Brouwers, P., G. Tudor-Williams, C. DeCarli, H. A. Moss, P. L. Wolters, L. A. Civitello, and P. A. Pizzzo. 1995. Relation between stage of disease and neurobehavioral measures in children with symptomatic HIV disease. AIDS 9:713-720.
6. Carpenter, T. O., A. Gerloczy, and J. Pitha. 1995. Safety of parenteral hydroxypropyl beta-cyclodextrin. J. Pharm. Sci. 84:222-225.
7. Chokekijchai, S., T. Shirasaka, J. N. Weinstein, and H. Mitsuya. 1995. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI. Antivir. Res. 28:25-38.
8. Collins, J. M., R. W. Klecker, J. A. Kelley, J. S. Roth, C. L. McCully, F. M. Balis, and D. G. Poplack. 1988. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:466-470.
9. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gil Aguado, J. G. de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, D. A. Cooper, and The European-Australian Collaborative Ritonavir Study Group. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
10. Gibaldi, M. and D. Perrier. 1982. Estimation of areas, p. 445-449. In J. Swarbrick (ed.), Pharmacokinetics. Marcel Dekker, Inc., New York, N.Y.
11. Hawkins, M. E., H. Mitsuya, C. M. McCully, K. S. Godwin, K. Murakami, D. G. Poplack, and F. M. Balis. 1995. Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. Antimicrob. Agents Chemother. 39:1259-1264.
12. Humphrey, R. W., B.-Y. Nguyen, K. M. Wyvill, L. E. Shay, J. Lietzau, T. Ueno, T. Fukasawa, H. Hayashi, H. Mitsuya, and R. Yarchoan. 1996. A phase I trial of HIV protease inhibitor KNI-272 in patients with AIDS or symptomatic HIV infection. In Proceedings of the XIth International Conference on AIDS.
13. Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
14. Kageyama, S., Y. Mimoto, Y. Murakawa, M. Nomizu, H. Ford, Jr., T. Shirasaka, S. Gulnik, J. Erickson, K. Takada, H. Hayashi, S. Broder, Y. Kiso, and H. Mitsuya. 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37:810-817.
15. Kiriyama, A., K. Fujita, S. Takemura, H. Kuramoto, Y. Kiso, and K. Takada. 1994. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration. Biopharm. Drug Dispos. 15:617-626.
16. Kiriyama, A., T. Mimoto, S. Kisanuki, Y. Kiso, and K. Takada. 1993. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations. Biopharm. Drug Dispos. 14:697-707.
17. Kitchen, V. S., C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J. N. Weber. 1995. Safety and activity of saquinavir in HIV infection. Lancet 345:952-955.
18. Knott, G. D. 1979. MLAB - a mathematical modeling tool. Comput. Programs Biomed. 10:261-280.
19. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
20. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
21. McCully, C. L., F. M. Balis, J. Bacher, J. Phillips, and D. G. Poplack. 1990. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab. Anim. Sci. 40:250-255.
22. National Research Council. 1996. Guide for the care and use of laboratory animals, p. 1-125. National Academy Press, Washington, D.C.
23. Noble, S., and D. Faulds. 1996. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
24. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
25. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.